Moleculin Biotech secures South Korean patent allowance for Annamycin reconstitution
MBRX•Moleculin Biotech received a South Korean patent allowance for its method of reconstituting liposomal Annamycin, expanding a portfolio covering three technology areas in more than 20 jurisdictions.




